The Fund supports networks of state health policy decision makers to help identify, inspire, and inform policy leaders.
The Milbank Memorial Fund supports two state leadership programs for legislative and executive branch state government officials committed to improving population health.
The Fund identifies and shares policy ideas and analysis to advance state health leadership, strong primary care, and sustainable health care costs.
Keep up with news and updates from the Milbank Memorial Fund. And read the latest blogs from our thought leaders, including Fund President Christopher F. Koller.
The Fund publishes The Milbank Quarterly, as well as reports, issues briefs, and case studies on topics important to health policy leaders.
The Milbank Memorial Fund is is a foundation that works to improve population health and health equity.
The Future of Population Health (Volume 101)
Quarterly Article
Magdalena Cerdá
Noa Krawczyk
Katherine Keyes
September 2024
December 2022
Back to The Milbank Quarterly
Policy Points:
Substance use and overdose are major drivers of morbidity and mortality in the United States. In 2020, a national survey of households estimated that 14.5% of individuals 12 years of age and older had a substance use disorder in the past year.1 Opioid use disorder (OUD) is estimated to affect at least 1% of the US population, but assessments that adjust for underreporting in national surveys indicate the true prevalence may be nearly fivefold greater.2 OUD is particularly concerning because of the associated high risk of overdose, which is caused by respiratory depression that can occur at high doses of opioids. In the last year, ending in October of 2021, over 100,000 US deaths were caused by an overdose, of which 75% involved opioids. Overdose remains the leading cause of injury death among all age groups and the leading cause of all deaths among adults 25–44 years old.3
The overdose epidemic, which collided with the COVID-19 pandemic in 2020, has been escalating over two decades. The nature of the crisis has evolved over time, including which regions and sociodemographic groups have been most impacted, as well as the types of drugs involved.4 In the early 2000s, overdose deaths were primarily driven by rising availability of prescribed pain medications instigated by increases in pharmaceutical opioid marketing to the medical field; in the early 2010s, increased prevalence of OUD, along with a new potent supply of illicit heroin, led to increases in overdoses driven primarily by heroin; by 2013, an influx of potent synthetic opioids, including illicitly manufactured fentanyl and related analogues, began infiltrating the illicit market and drove up overdose death rates. Since 2015, overdoses have increasingly involved a combination of opioids (mostly fentanyl) with illicit stimulants such as cocaine and methamphetamine. And although earlier phases of the crisis saw sharp rises in overdose death rates among White and American Indian/Alaska Native individuals, later phases have been associated with rapidly rising death rates among Black and Hispanic individuals and sustained increases among American Indian/Alaska Native individuals.5,6
As the overdose crisis continues to escalate, we must reflect on past challenges and lessons learned so that we may develop fruitful strategies to address this epidemic in the future. In this paper, we summarize past successes, ongoing challenges, and potential solutions to address substance use and overdose in the context of primary, secondary, and tertiary prevention efforts.We then discuss implications for broader policy, training, and leadership in the field that could address current and future substance use crises in the United States and beyond.